Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies

AIMS: Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next‐generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP‐5862) vs. efficacy and safety responses in patients with B‐cell malignancies who received acalabrutinib as monotherapy or i...

Descripción completa

Detalles Bibliográficos
Autores principales: Edlund, Helena, Buil‐Bruna, Núria, Vishwanathan, Karthick, Wei, Helen, Raman, Rakesh, de Kock, Miné, He, Zhongqing, Liu, Huan, Baek, Marshall, Ware, Joseph, Patel, Priti, Tomkinson, Helen, Sharma, Shringi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298019/
https://www.ncbi.nlm.nih.gov/pubmed/34532877
http://dx.doi.org/10.1111/bcp.15087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298019/
https://www.ncbi.nlm.nih.gov/pubmed/34532877
http://dx.doi.org/10.1111/bcp.15087

Ejemplares similares